What happened
Chinese AI-driven drug-design firms secured US$75 billion in out-licensing deals with global pharmaceutical companies during the first five months of 2026, a significant increase from zero before 2020, per HSBC's Linda Shu. Metis TechBio, an AI-driven drug-design company, signed an agreement with Boulevard Bio for its cancer drug candidate MTS-128, involving a US$20 million upfront payment and up to US$1.6 billion in milestone payments. AI integration can shorten development timelines to 18 months. AstraZeneca's US$18.5 billion collaboration with CSPC Pharmaceutical Group and Eli Lilly's US$345 million agreement with Ailux also occurred.
Why it matters
Global pharmaceutical procurement teams and R&D leads face increasing pressure to replenish pipelines as blockbuster drug patents expire post-2030. This surge in Chinese AI drug-design deals offers a mechanism to acquire novel candidates, with US$75 billion committed in five months alone. The trend follows broader advancements in AI accelerating drug discovery for diseases, as seen with Google DeepMind AI research. However, the sector operates under a policy overhang, including US restrictions like the Biotech Investment National Security Act and China's anti-corruption policies, which could impact business development and domestic sales growth.
